Company intelligence / Profile preview
NGM Biopharmaceuticals
South San Francisco, California, United Statesngmbio.com ↗
- Ownership
- Public · NGM
- Employees
- ~129
- Development stage
- Phase 2
01
Overview
NGM Bio has a robust pipeline of biologics primarily focused on monoclonal antibodies targeting novel pathways in oncology and metabolic/liver diseases. Recent clinical results include:
- Ongoing Phase 1/2 trial of NGM707 + pembrolizumab in advanced/metastatic solid tumors.
- Completed enrollment for Phase 1b trials of NGM831 + pembrolizumab and NGM438 + pembrolizumab in solid tumors.
- Completed a Phase 2 trial of NGM120 for metastatic pancreatic cancer; no clear efficacy signal detected—oncology development paused. However, development continues for hyperemesis gravidarum with ongoing discussions with the FDA. Aldafermin remains under consideration for PSC pending further regulatory guidance and capital availability.
- Therapeutic areas
- Women's HealthOncologyGastroenterologyEndocrinology
- Modalities
- AntibodyMonoclonal antibodyProtein
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Merck & Co.: Strategic R&D collaboration including licensing option rights to certain assets such as MK‑3655.KdT Ventures agreement regarding the FGFR agonist program.
Beyond the preview
Go deeper on NGM Biopharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NGM Biopharmaceuticals.